Associated Papers
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T et al.
Cancer Cell, 2009
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A et al.
Leukemia Research, 2008
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
MacPartlin M et al.
Leukemia, 2008
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
Miething C et al.
Leukemia, 2006
Select a paper to view details